ReviewEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2014
Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia.
Review in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Altered brain functional networks in schizophrenia with persistent negative symptoms: an activation likelihood estimation meta-analysis.Frontiers in human neuroscience · 2023Pooled it
- Hydrogel-Based Depot Systems in Psychiatric Pharmacotherapy: A Narrative Review Rethinking Long-Acting Drug Delivery.Gels (Basel, Switzerland) · 2026Review
- Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis.F1000Research · 2024Article
- Effort-related effects of chronic administration of the DA DPsychopharmacology · 2023Article
- GDNF gene therapy for alcohol use disorder in male non-human primates.Nature medicine · 2023Article
- Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.Wellcome open research · 2023Article
- Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives.Psychopharmacology · 2022Review
- Clinical and Preclinical Assessments of Anhedonia in Psychiatric Disorders.Current topics in behavioral neurosciences · 2022Article
- Histamine HNature communications · 2021Article
- Prevention of schizophrenia deficits via non-invasive adolescent frontal cortex stimulation in rats.Molecular psychiatry · 2020Article
- Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.Clinical psychological science : a journal of the Association for Psychological Science · 2019Article
- Neural correlates of positive and negative symptoms through the illness course: an fMRI study in early psychosis and chronic schizophrenia.Scientific reports · 2019Article
- An Overview of Animal Models Related to Schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2019Review
- Rat models of reward deficits in psychiatric disorders.Current opinion in behavioral sciences · 2018Review
- Parvalbumin-containing GABA cells and schizophrenia: experimental model based on targeted gene delivery through adeno-associated viruses.Behavioural pharmacology · 2017Article
- Human iPSC Glial Mouse Chimeras Reveal Glial Contributions to Schizophrenia.Cell stem cell · 2017Article
- Modeling hypohedonia following repeated social defeat: Individual vulnerability and dopaminergic involvement.Physiology & behavior · 2017Article
- Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.Schizophrenia bulletin · 2017Review
- Modelling depression in animals: at the interface of reward and stress pathways.Psychopharmacology · 2017Review
- Special issue: recognizing the lifetime scientific contributions of Athina Markou.Psychopharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Schizophrenia represents a complex, heterogeneous disorder characterized by several symptomatic domains that include positive and negative symptoms and cognitive deficits. Negative symptoms reflect a cluster of symptoms that remains therapeutically unresponsive to currently available medications. Therefore, the development of animal models that may contribute to the discovery of novel and efficacious treatment strategies is essential. An animal model consists of both an inducing condition or manipulation (i.e., independent variable) and an observable measure(s) (i.e., dependent variables) that are used to assess the construct(s) under investigation. The objective of this review is to describe currently available experimental procedures that can be used to characterize constructs relevant to the negative symptoms of schizophrenia in experimental animals. While negative symptoms can encompass aspects of social withdrawal and emotional blunting, this review focuses on the assessment of reward deficits that result in anhedonia, avolition, and abnormal reward anticipation. The development and utilization of animal procedures that accurately assess reward-based constructs related to negative symptomatology in schizophrenia will provide an improved understanding of the neural substrates involved in these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.